MoonLake Immunotherapeutics (MLTX) Return on Invested Capital (2022)
MoonLake Immunotherapeutics' (MLTX) quarterly Return on Invested Capital came in at 0.07% in Q3 2022, down 9.11% quarter-over-quarter from 0.06% in Q2 2022.
MoonLake Immunotherapeutics (MLTX) Return on Invested Capital (2022) Analysis & Trends
MoonLake Immunotherapeutics' Return on Invested Capital history runs 1 years deep, the most recent figure standing at 0.07% for Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | MoonLake Immunotherapeutics | 1.35 Bn | 991.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -0.07% |
| Jun 30, 2022 | -0.06% |
| Mar 31, 2022 | -0.07% |